Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria

被引:337
作者
Foligne, Benoit
Nutten, Sophie
Grangette, Corinne
Dennin, Veronique
Goudercourt, Denise
Poiret, Sabine
Dewulf, Joelle
Brassart, Dominique
Mercenier, Annick
Pot, Bruno
机构
[1] Inst Pasteur, F-59019 Lille, France
[2] Nestle Nutr, Vevey, Switzerland
[3] Nestle Res Ctr, Dept Nutr & Hlth, CH-1000 Lausanne, Switzerland
关键词
inflammatory bowel disease; probiotics; cytokines; peripheral blood mononuclear cells; trinitrobenzene sulfonate-induced colitis;
D O I
10.3748/wjg.v13.i2.236
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the correlation between in vitro and in vivo immunomodulation potential of the probiotic strain and its ability to prevent experimental colitis in mice. METHODS: In vitro immunomodulation was assessed by measuring interleukin (IL)-12p70, IL-10, tumor necrosis factor alpha (TNF alpha) and interferon gamma (IFN gamma) release by human peripheral blood mononuclear cells (PBMCs) after 24 h stimulation with 13 live bacterial strains. A murine model of acute TNBS-colitis was next used to evaluate the prophylactic protective capacity of the same set of strains. RESULTS: A strain-specific in vivo protection was observed. The strains displaying an in vitro potential to induce higher levels of the anti-inflammatory cytokine IL-10 and lower levels of the inflammatory cytokine IL-12, offered the best protection in the in vivo colitis model. In contrast, strains leading to a low IL-10/IL-12 cytokine ratio could not significantly attenuate colitis symptoms. CONCLUSION:These results show that we could predict the In vivo protective capacity of the studied lactic acid bacteria (LAB) based on the cytokine profile we established in vitro. The PBMC-based assay we used may thus serve as a useful primary indicator to narrow down the number of candidate strains to be tested in murine models for their anti-inflammatory potential. (c) 2007 The WIG Press. All rights reserved.
引用
收藏
页码:236 / 243
页数:8
相关论文
共 43 条
[1]  
[Anonymous], 1989, Molecular Cloning
[2]   Probiotics as a treatment strategy for gastrointestinal diseases? [J].
Bergonzelli, GE ;
Blum, S ;
Brüssow, H ;
Corthésy-Theulaz, I .
DIGESTION, 2005, 72 (01) :57-68
[3]   Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function [J].
Braat, H ;
van den Brande, J ;
van Tol, E ;
Hommes, D ;
Peppelenbosch, M ;
van Deventer, S .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2004, 80 (06) :1618-1625
[4]   Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation [J].
Chapat, L ;
Chemin, K ;
Dubois, B ;
Bourdet-Sicard, R ;
Kaiserlian, D .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (09) :2520-2528
[5]   Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells [J].
Christensen, HR ;
Frokiær, H ;
Pestka, JJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (01) :171-178
[6]   Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies? [J].
Cross, ML ;
Gill, HS .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2001, 125 (02) :112-119
[7]   Probiotics and the management of inflammatory bowel disease [J].
Fedorak, RN ;
Madsen, KL .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (03) :286-299
[8]   Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria:: Technical and microbiological aspects [J].
Foligné, B ;
Nutten, S ;
Steidler, L ;
Dennin, V ;
Goudercourt, D ;
Mercenier, A ;
Pot, B .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (02) :390-400
[9]  
Foligné B, 2005, GUT, V54, P727
[10]   The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance [J].
Fujiwara, D ;
Inoue, S ;
Wakabayashi, H ;
Fujii, T .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2004, 135 (03) :205-215